Secretin

Summary

Secretin (CHEMBL6067494) is an approved protein (ATC V04CK01) targeting SCTR, ADCYAP1R1, and VIPR1; indicated across 6 conditions including autism and obesity disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: V04CK01
• Targets: 4 (SCTR, ADCYAP1R1, VIPR1…)
• Indications: 6 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6067494
Name	Secretin
Type	Protein
Max phase	4
ATC	V04CK01

Also known as: Secretin, Secretin (human, porcine, etc.), unspecified, Secretin-ferring, Secretina, Secretine, HSDGTFTSELSRLQDSARLQRLLQGLV-NH2, SECRETIN, secretin

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SCTR	secretin receptor	Agonist	9	0.5%	P47872
ADCYAP1R1	PAC1 receptor	Agonist	4.5	0.2%	P41586
VIPR1	VPAC1 receptor	Agonist	5	0.1%	P32241
VIPR2	VPAC2 receptor	Agonist	5.3	1.2%	P41587

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Glucagon-like peptide 1 receptor, Secretin receptor.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SCTR	10.1	EC50	0.08	nM	CHEMBL_ACT_3502939
SCTR	8.46	Ki	3.5	nM	CHEMBL_ACT_3502937
GLP1R	5.64	EC50	2300	nM	CHEMBL_ACT_25915230

Target pathways

Aggregated over 4 target gene(s): SCTR, ADCYAP1R1, VIPR1, VIPR2.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
G alpha (s) signalling events	4	ADCYAP1R1, SCTR, VIPR1, VIPR2
Glucagon-type ligand receptors	4	ADCYAP1R1, SCTR, VIPR1, VIPR2
Signal Transduction	1	SCTR
NGF-independant TRKA activation	1	ADCYAP1R1
Signaling by GPCR	1	SCTR
Class B/2 (Secretin family receptors)	1	SCTR
GPCR downstream signalling	1	SCTR
GPCR ligand binding	1	SCTR

Dominant GO biological processes

GO term	Targets
cell surface receptor signaling pathway	4
G protein-coupled receptor signaling pathway	4
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	4
adenylate cyclase-activating G protein-coupled receptor signaling pathway	4
signal transduction	4
diet induced thermogenesis	1
intracellular water homeostasis	1
response to nutrient levels	1
regulation of appetite	1
regulation of synaptic plasticity	1
spermatogenesis	1
response to xenobiotic stimulus	1
positive regulation of calcium ion transport into cytosol	1
cell differentiation	1
response to estradiol	1

Indications & clinical

Indications

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
autism	3	MONDO:0005260	EFO:0003758
obesity disorder	2	MONDO:0011122	EFO:0001073
pancreatitis	2	MONDO:0004982	EFO:0000278
chronic pancreatitis	1	MONDO:0005003	EFO:0000342
dyspepsia	1	MONDO:0002268	EFO:0008533

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE3	3
Not specified	3
PHASE4	2
PHASE2	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05659147	PHASE4	ENROLLING_BY_INVITATION	Imaging Biomarkers of Pancreatic Function and Disease
NCT01134848	PHASE4	COMPLETED	A Study of Serial Magnetic Resonance Cholangiopancreatography (MRCP) Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers
NCT02000089	PHASE3	RECRUITING	The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT02160808	PHASE2/PHASE3	COMPLETED	Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection
NCT05914077	PHASE3	UNKNOWN	Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia.
NCT00235274	PHASE2	COMPLETED	Effects of RG1068 (Secretin) on Information Processing in Schizophrenia
NCT02458118	PHASE1/PHASE2	UNKNOWN	Pancreatic Perfusion Using Secretin and MRI
NCT03686618	PHASE2	UNKNOWN	Secretin for Acute Pancreatitis
NCT01452217	PHASE1	COMPLETED	Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers
NCT01094626	Not specified	WITHDRAWN	Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection
NCT02869893	Not specified	COMPLETED	MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
NCT04613700	Not specified	COMPLETED	The Role of Secretin on the Energy Homeostasis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

3 molecules share ≥1 primary target. Top 3 by shared-target count:

Molecule	Source	Status	Shared targets
MK-0893	ChEMBL	Phase 2	VIPR1, VIPR2
Belzutifan	PubChem	Approved	VIPR1, VIPR2
AVIPTADIL	ChEMBL	Phase 3	VIPR2